What are the treatment options for platinum-resistant ovarian cancer?
When ovarian cancer progresses within six months of platinum-based chemotherapy, it's considered platinum-resistant. This can feel overwhelming, but there are several treatment paths worth exploring with your oncologist.
Here's a summary of the main options Show Full Answer
What are the treatment options for platinum-resistant ovarian cancer?
When ovarian cancer progresses within six months of platinum-based chemotherapy, it's considered platinum-resistant. This can feel overwhelming, but there are several treatment paths worth exploring with your oncologist.
Here's a summary of the main options available:
Non-Platinum Chemotherapy
- Gemcitabine
- Paclitaxel
- Pegylated liposomal doxorubicin (PLD)
- Topotecan
These options tend to have similar outcomes, and your oncologist will recommend one based on your overall health, prior treatments, and other personal factors. Targeted Therapies
- Mirvetuximab soravtansine-gynx (Elahere) — FDA-approved in 2024 for platinum-resistant epithelial ovarian cancer that tests positive for a protein called folate receptor-alpha
- PARP inhibitors — may be an option depending on your genetic mutations (e.g., BRCA)
- Relacorilant (Lifyorli) — FDA-approved in March 2026, used in combination with nab-paclitaxel, typically after one to three prior treatment regimens that included bevacizumab Clinical Trials
Joining a clinical trial can open doors to newer treatments not yet widely available. Researchers are actively studying genes that influence platinum resistance, and new therapies are emerging. It's worth asking your oncologist if any trials are a good fit for your situation.
Every treatment decision should be made together with your oncologist, weighing the potential benefits against side effects and your personal preferences. You deserve a plan that works for *you*.
June 27
Continue with Facebook
Continue with Email
Join
Your Privacy Choices
